A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax™), a novel bioenhanced preparation of curcumin

Indian Journal of Pharmaceutical Sciences

Volumn 70, Issue 4, 2008, Pages 445-449

  Antony, B ^a   Merina, B ^a   Iyer, V ^a   Judy, N ^b   Lennertz, K ^c   Joyal, S ^c  

^a Arjuna Natural Extracts Ltd   (India)

^b Little Flower Hospital   (India)

^c Life Extension Foundation   (United States)

Author keywords

Anticancer; Antioxidant; Bioavailability; Biocurcumax; Curcuma longa; Curcumin

Indexed keywords

BCM 95 CG; BIOCURCUMAX; CURCUMIN; PHOSPHATIDYLCHOLINE; PIPERINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PILOT STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 58149084882     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.44591     Document Type: Article

References (45)

1. Maheshwari RK, Sing AK, Gaddipati J, Srimal RC. Multiple biological effects of curcumin: A short review. Life Sci 2006;78:2081-7.
2. Bengmark S. Curcumin, a toxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: A shield against acute and chronic diseases. J Parenter Enter Nutr 2006;30:45-51.
3. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
4. Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. Eur J Cancer 2005;41:1955-68.
5. Duvoix A, Blasius R, Delhelle S, Schnekenburger M, Morceau F, Henry E, et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005;223:181-90.
6. Joe B, Vijayakumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 2004;44:97-111.
7. Arajuo CC, Leon LL. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 2001;96:723-8.
8. Lao CD, Ruffin MT 4th, Normolle D, Health DD, Murray SI, Baily JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement. Altern Med 2006;6:10-13.
9. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
10. Jagetia GC, Aggarwal BB, "Spicing up" the immune system by curcumin. J Clin Immunol 2007;27:19-35.
11. Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, Lahiry L, et al. Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: Protection by curcumin. Cancer Res 2007;67:362-70.
12. Churchill M, Chadburn A, Bilinski RT, Bertagnolli MM. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. J Surg Res 2000;89:169-75.
13. Pal S, Bhattacharyya S, Choudhuri T. Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumor-bearing mice by curcumin. Cancer Detect Prev 2005;29:470-8.
14. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11:535-40.
15. South EH, Exon JH, Hendrix K. Dietary curcumin enhances antibody response in rats. Immunopharmacol Immunotoxicol 1997;19:105-19.
16. Kurup VP, Barrios CS, Raju R, Jhonson BD, Levy MB, Fink JN. Immune response modulation by curcumin in a latex allergy model. Clin Mol Allergy 2007;5:1-12.
17. Xu Y, Ku B, Tie L. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006;1122:56-64.
18. Kim GY, Kim KH, Lee SH, Yoon MS, Lee HJ, Moon DO, et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 2005;174:8116-24.
19. Bhattacharyya S, Mandal D, Saha B. Curcumin prevents tumor-induced apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 2007;282:15954-64.
20. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005;2:131-6.
21. Shishodia S, Sethi G, Aggarwal BB. Curcumin: Getting back to the roots. NY Acad Sci 2005;1056:206-17.
22. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978;43:86-92.
23. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology 1981;20:251-7.
24. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 1978;8:761-8.
25. Ravindranath V, Chandrasekhara N. Metabolism of curcumin - studies with [3H] curcumin. Toxicology 1982;22:337-44.
26. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980;16:259-65.
27. Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 2000;67:2785-93.
28. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Disp 1999;27:486-94.
29. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat In Vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001;61:1058-64.
30. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer preventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:105-11.
31. Hoehle SI, Pfeiffer E, Solyom AM, Metzler M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J Agr Food Chem 2006;54:756-64.
32. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-900.
33. Garcea G, Berry DP, Jones DJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005;14:120-5.
34. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-54.
35. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-6.
36. Piyachaturawat P, Glinsukon T, Toskulkao C. Acute and subacute toxicity of piperine in mice, rats and hamsters. Toxicol Lett 1983;16:351-9.
37. Daware MB, Mujumdar AM, Ghaskadbi S. Reproductive Toxicity of Piperine in Swiss Albino Mice. Planta Med 2000;66:231-6.
38. Panda S, Kar A. Piperine Lowers the Serum Concentrations of Thyroid Hormones, Glucose and Hepatic 5′D Activity in Adult Male Mice. Horm Metab Res 2003;35:523-6.
39. Unchern S, Saito H, Nishiyama N. Death of Cerebellar Granule Neurons Induced by Piperine Is Distinct from that Induced by Low Potassium. Neurochem Res 1998;23:97-102.
40. Marczylo TH, Verschoyle RD, Cooke DN. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007;60:171-7.
41. Li L, Bratiteh FS, Kurzrock R. Liposome-encapsulated curcumin: In vitro and In Vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005;104:1322-31.
42. Kumar V, Lewis SA, Mutalik S, Shenoy DB, Venkatesh, Udupa N. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 2002;46:209-17.
43. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): A novel strategy for human cancer therapy. J Nanobiotechnol 2007;5:3-21.
44. Antony B, A composition to enhance the bioavailability of curcumin, WO2006129323, Arjuna Natural Extracts Ltd; 2006.
45. Merina B, Antony B. Bioavailability of Biocurcumax™ (BCM-95™). Spice India 2006;19:11-15.